Human Herpesvirus 6 (HHV 6) in Hematopoietic Cell Transplantation (HCT) and Immune Effector Cells (IEC): Controversies in Surveillance and Management - Enduring
Allogeneic Hematopoietic Cell Transplantation (HCT) patients and those who undergo CAR T Cell therapy are at high risk for infectious complications, including Human Herpesvirus 6 (HHV6). Even though up to 40% of allogeneic HCT patients may reactivate HHV6 within the first 1-3 months after allogeneic HCT, there is lack of data in determining the role of surveillance and pre-emptive treatment of HHV6 viremia. This is particularly the case in CAR T, where we do not have good data on reactivation rates or disease incidence.
Since the major complication of encephalitis from HHV6 is very infrequent despite high reactivation rates, it is unclear who will develop this disease even if they have viral reactivation. There is a lack of large RCT's and evidence is limited to small open-label clinical trials and heterogeneity in treatments for hematologic malignancies leading to HCT. It is imperative to stay abreast on the controversies in surveillance and management of this disease.
All physicians and HCT and Infectious Disease APP's.
- Demonstrate knowledge on when to treat Human Herpes Virus 6 (HHV6) infection.
- Outline various HHV6 syndromes and approaches to evaluation and management.
- Identify risk factors for severe HHV6 infection.
- Identify limitations of preemptive antiviral therapy for asymptomatic HHV6 viremia.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Joshua Hill has indicated the following relevant financial relationships: Consultant/Advisor for AlloVir.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
This activity has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.25
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.25 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Human Herpesvirus 6 (HHV 6) in Hematopoietic Cell Transplantation (HCT) and Immune Effector Cells (IEC): Controversies in Surveillance and Management - Enduring for a maximum of 1.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.
In order to earn credit for this activity, participants must:
- Read learning objectives and faculty disclosures
- View Enduring Activity Video
- Complete the evaluation
Upon satisfactory completion, you will have the option to receive a print out of your certificate.
Estimated timeframe for completion of this activity, including the time to complete the evaluation is 1.25 hour.